Literature DB >> 499320

Pharmacokinetics of metformin after intravenous and oral administration to man.

P J Pentikäinen, P J Neuvonen, A Penttilä.   

Abstract

The kinetics of 14C-metformin have been studied in five healthy subjects after oral and intravenous administration. The intravenous dose was distributed to a small central compartment of 9.9 +/- 1.61 (X +/- SE), from which its elimination could be described using three-compartment open model. The elimination half-life from plasma was 1.7 +/- 0.1 h. Urinary excretion data revealed a quantitatively minor terminal elimination phase with a half-life of 8.9 +/- 0.7 h. After the intravenous dose, metformin was completely excreted unchanged in urine with a renal clearance of 454 +/- 47 ml/min. Metformin was not bound to plasma proteins. The concentration of metformin in saliva was considerably lower than in plasma and declined more slowly. The bioavailability of metformin tablets averaged 50--60%. The rate of absorption was slower than that of elimination, which resulted in a plasma concentration profile of "flip-flop" type for oral metformin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 499320     DOI: 10.1007/bf00562061

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Drug concentration in saliva.

Authors:  J C Mucklow; M R Bending; G C Kahn; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1978-11       Impact factor: 6.875

Review 2.  [Pharmacokinetics of blood glucose lowering biguanide derivatives].

Authors:  H Mehnert
Journal:  Acta Diabetol Lat       Date:  1969-09

3.  Metformin administration in hyperlipidemic states.

Authors:  A Gustafson; P Björntorp; M Fahlén
Journal:  Acta Med Scand       Date:  1971-12

4.  [Absorption, distribution in the organism and elimination of metformin].

Authors:  R Beckmann
Journal:  Diabetologia       Date:  1969-10       Impact factor: 10.122

5.  Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.

Authors:  M Ehrnebo; S Agurell; B Jalling; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

6.  Biguanides and lactic acidosis in diabetics.

Authors: 
Journal:  Br Med J       Date:  1977-12-03

7.  Biguanides and lactic acidosis.

Authors:  P J Phillips; D W Thomas; P E Harding
Journal:  Br Med J       Date:  1977-01-22

8.  Epidemiology of adverse drug reactions to phenformin and metformin.

Authors:  U Bergman; G Boman; B E Wiholm
Journal:  Br Med J       Date:  1978-08-12

9.  Aminopyrine demethylation measured by breath analysis in cirrhosis.

Authors:  J Bircher; A Küpfer; I Gikalov; R Preisig
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

10.  Effect of metformin on lipid metabolism in the rabbit aortic wall.

Authors:  G Marquié
Journal:  Atherosclerosis       Date:  1978-07       Impact factor: 5.162

View more
  83 in total

Review 1.  Cardiovascular impact of drugs used in the treatment of diabetes.

Authors:  Chris R Triggle; Hong Ding
Journal:  Ther Adv Chronic Dis       Date:  2014-11       Impact factor: 5.091

2.  Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus.

Authors:  Christophe Bardin; Estelle Nobecourt; Etienne Larger; François Chast; Jean-Marc Treluyer; Saik Urien
Journal:  Eur J Clin Pharmacol       Date:  2012-01-25       Impact factor: 2.953

3.  Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1 and 3A1/2 for the metabolism of metformin.

Authors:  Y H Choi; M G Lee
Journal:  Br J Pharmacol       Date:  2006-08-29       Impact factor: 8.739

4.  Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers.

Authors:  Mette Marie Hougaard Christensen; Kurt Højlund; Ole Hother-Nielsen; Tore Bjerregaard Stage; Per Damkier; Henning Beck-Nielsen; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2015-05-05       Impact factor: 2.953

5.  Effects of Pregnancy on the Pharmacokinetics of Metformin.

Authors:  Michael Z Liao; Shannon K Flood Nichols; Mahmoud Ahmed; Shannon Clark; Gary D Hankins; Steve Caritis; Raman Venkataramanan; David Haas; Sara K Quinney; Laura S Haneline; Alan T Tita; Tracy Manuck; Joanne Wang; Kenneth E Thummel; Linda Morris Brown; Zhaoxia Ren; Thomas R Easterling; Mary F Hebert
Journal:  Drug Metab Dispos       Date:  2020-01-24       Impact factor: 3.922

6.  Intestinal permeability of metformin using single-pass intestinal perfusion in rats.

Authors:  Nai-Ning Song; Quan-Sheng Li; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

7.  The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects.

Authors:  Yi Ding; YanYan Jia; Ying Song; ChengTao Lu; YuWen Li; MinChun Chen; MingMing Wang; AiDong Wen
Journal:  Eur J Clin Pharmacol       Date:  2013-10-30       Impact factor: 2.953

Review 8.  Use of metformin in diseases of aging.

Authors:  John M Miles; Andrew D Rule; Barry A Borlaug
Journal:  Curr Diab Rep       Date:  2014-06       Impact factor: 4.810

9.  A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function.

Authors:  Janna K Duong; M Y A M Kroonen; S S Kumar; H L Heerspink; C M Kirkpatrick; G G Graham; K M Williams; R O Day
Journal:  Eur J Clin Pharmacol       Date:  2017-04-28       Impact factor: 2.953

10.  The Association between Metformin Therapy and Lactic Acidosis.

Authors:  Isabelle H S Kuan; Ruth L Savage; Stephen B Duffull; Robert J Walker; Daniel F B Wright
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.